What are your thoughts on the July 02, 2024 from Seeking Alpha *Ardelyx (NASDAQ:ARDX) stock tumbled 32% Tuesday after the company said it has decided not to apply to include its drug Xphozah in the US Centers for Medicare and Medicaid Services’ Transitional Drug Add-on Payment Adjustment, or TDAPA, program for certain renal disease drugs." Price target has been lowered from $13 to $10 per Share. Thanks and keep up the good work.
It sucks to put it mildly, There is still a chance for the bill to pass which would allow full access. I understand ARDX thoughts, about trying to make it more available , but they shouldnt have to, I believe it will hurt future drug prospects for all companies, so my hope is there enough to push it through
